Castle Biosciences (NASDAQ:CSTL) Insider Sells $483,594.50 in Stock

Castle Biosciences, Inc. (NASDAQ:CSTL) insider Derek Maetzold sold 18,650 shares of the firm’s stock in a transaction that occurred on Tuesday, March 17th. The shares were sold at an average price of $25.93, for a total transaction of $483,594.50. Following the completion of the transaction, the insider owned 22,129 shares of the company’s stock, valued at approximately $573,804.97. This trade represents a 45.73% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link.

Castle Biosciences Trading Up 0.4%

CSTL traded up $0.09 during trading on Thursday, reaching $25.70. 209,769 shares of the company’s stock were exchanged, compared to its average volume of 418,124. The company has a current ratio of 5.26, a quick ratio of 5.11 and a debt-to-equity ratio of 0.02. Castle Biosciences, Inc. has a one year low of $14.59 and a one year high of $44.28. The firm has a fifty day moving average price of $33.79 and a two-hundred day moving average price of $31.74. The stock has a market capitalization of $764.06 million, a PE ratio of -30.24 and a beta of 1.09.

Castle Biosciences (NASDAQ:CSTL) last released its quarterly earnings results on Thursday, February 26th. The company reported ($0.08) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.23) by $0.15. The firm had revenue of $81.88 million during the quarter, compared to the consensus estimate of $81.19 million. Castle Biosciences had a negative net margin of 7.02% and a negative return on equity of 0.89%. As a group, equities research analysts forecast that Castle Biosciences, Inc. will post 0.44 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Castle Biosciences

Several large investors have recently added to or reduced their stakes in CSTL. AIGH Capital Management LLC acquired a new stake in shares of Castle Biosciences during the 3rd quarter worth approximately $16,105,000. Schroder Investment Management Group boosted its stake in Castle Biosciences by 8.6% during the second quarter. Schroder Investment Management Group now owns 648,572 shares of the company’s stock worth $13,198,000 after acquiring an additional 51,483 shares in the last quarter. Campbell & CO Investment Adviser LLC acquired a new stake in Castle Biosciences in the third quarter worth $615,000. Squarepoint Ops LLC grew its holdings in Castle Biosciences by 29.1% in the second quarter. Squarepoint Ops LLC now owns 125,719 shares of the company’s stock worth $2,567,000 after purchasing an additional 28,359 shares during the period. Finally, Universal Beteiligungs und Servicegesellschaft mbH increased its stake in Castle Biosciences by 364.6% in the second quarter. Universal Beteiligungs und Servicegesellschaft mbH now owns 54,610 shares of the company’s stock valued at $1,115,000 after purchasing an additional 42,857 shares in the last quarter. Institutional investors and hedge funds own 92.60% of the company’s stock.

Analyst Upgrades and Downgrades

CSTL has been the topic of several recent research reports. Lake Street Capital lifted their target price on Castle Biosciences from $35.00 to $52.00 and gave the stock a “buy” rating in a report on Monday, January 12th. Morgan Stanley upgraded Castle Biosciences to a “buy” rating in a research report on Monday, March 2nd. BTIG Research upped their target price on Castle Biosciences from $38.00 to $50.00 and gave the company a “buy” rating in a report on Friday, December 12th. Weiss Ratings reissued a “sell (d)” rating on shares of Castle Biosciences in a research report on Monday, December 29th. Finally, KeyCorp restated an “overweight” rating and issued a $50.00 price target on shares of Castle Biosciences in a research report on Thursday, January 29th. Eight analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus price target of $47.57.

About Castle Biosciences

Castle Biosciences, Inc is a molecular diagnostics company specializing in the development and commercialization of prognostic and diagnostic tests for patients with dermatologic conditions. The company’s proprietary portfolio of genomic assays is designed to improve risk assessment and guide clinical decision-making for individuals with skin cancers and other skin-related diseases. By combining genomic data with advanced statistical algorithms, Castle Biosciences seeks to provide actionable insights that help physicians tailor treatment plans and monitoring strategies.

The company’s flagship test, DecisionDx-Melanoma, evaluates the probability of metastasis in patients diagnosed with cutaneous melanoma, supporting more personalized surveillance and therapeutic approaches.